Juno Therapeutics (JUNO) reported earnings on Mon 9 May 2016 (a/h)

** charts before earnings **

 

** charts after earnings **

 

Juno Therapeutics misses by $0.26, beats on revs; reaffirms cash burn guidance :

• Reports Q1 (Mar) loss of $0.78 per share, excluding non-recurring items, $0.26 worse than the Capital IQ Consensus of ($0.52); rev $9.8 mln vs. $3.2 mln consensus.
• -- JuMP manufacturing facility operational for JCAR015 Phase II ROCKET trial
• Reaffirm: Juno expects 2016 cash burn, excluding cash inflows or outflows from business development activities, to be between $220 million and $250 million. Operating burn estimated to be between $170 million and $195 million.